6.45
0.04 (0.62%)
| Previous Close | 6.41 |
| Open | 6.48 |
| Volume | 581,766 |
| Avg. Volume (3M) | 514,433 |
| Market Cap | 666,843,264 |
| Price / Book | 5.99 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -1.90 |
| Total Debt/Equity (MRQ) | 14.41% |
| Current Ratio (MRQ) | 11.06 |
| Operating Cash Flow (TTM) | -78.71 M |
| Levered Free Cash Flow (TTM) | -47.17 M |
| Return on Assets (TTM) | -32.92% |
| Return on Equity (TTM) | -56.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Aura Biosciences, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | -0.10 |
|
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.98% |
| % Held by Institutions | 76.19% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Matrix Capital Management Company, Lp | 31 Mar 2026 | 6,922,870 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BITETTI TERESA MARIE | 6.21 | - | 15,000 | 93,150 |
| JOHNSON DAVID MICHAEL | 6.21 | - | 15,000 | 93,150 |
| MATTESSICH ANTONY C. | 6.21 | - | 15,000 | 93,150 |
| SRIVASTAVA SAPNA | 6.21 | - | 15,000 | 93,150 |
| Aggregate Net Quantity | 60,000 | |||
| Aggregate Net Value ($) | 372,600 | |||
| Aggregate Avg. Buy ($) | 6.21 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MATTESSICH ANTONY C. | Director | 11 Jun 2026 | Acquired (+) | 15,000 | 6.21 | 93,150 |
| JOHNSON DAVID MICHAEL | Director | 11 Jun 2026 | Acquired (+) | 15,000 | 6.21 | 93,150 |
| SRIVASTAVA SAPNA | Director | 11 Jun 2026 | Acquired (+) | 15,000 | 6.21 | 93,150 |
| BITETTI TERESA MARIE | Director | 11 Jun 2026 | Acquired (+) | 15,000 | 6.21 | 93,150 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |